|Mr. Aron Marc Knickerbocker||Pres, CEO & Director||731.07k||24.2k||1969|
|Mr. David V. Smith||Exec. VP & CFO||454.98k||N/A||1960|
|Mr. Francis W. Sarena||Chief Strategy Officer & Sec.||640.93k||N/A||1971|
|Dr. Helen Louise Collins||Sr. VP & Chief Medical Officer||610k||N/A||1963|
|Mr. David White||Principal Accounting Officer||N/A||N/A||1964|
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Five Prime Therapeutics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 8.